All In Biotech

Drug Trial Radar · NCT07571174

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

May 14, 2026

Primary completion

Jun 2029

Study completion Jun 2029

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • LY4256984Drug

    Administered IT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline Up to Week 96

Locations

11 sites in 5 countries. Site status is shown where the registry gives one.

  • UZ Leuven

    Leuven, Belgium · Not yet recruiting

  • Heritage Medical Research Clinic

    Calgary, Canada · Not yet recruiting

  • University Hospital - London Health Sciences Centre

    London, Canada · Not yet recruiting

  • McGill University Health Centre

    Montreal, Canada · Recruiting

  • Sunnybrook Research Institute

    Toronto, Canada · Recruiting

  • Universitätsklinikum Schleswig-Holstein

    Lübeck, Germany · Not yet recruiting

  • Universitätsmedizin Rostock

    Rostock, Germany · Not yet recruiting

  • Universitaetsklinikum Ulm

    Ulm, Germany · Not yet recruiting

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands · Not yet recruiting

  • Hospital Universitari de Bellvitge

    L'Hospitalet de Llobregat, Spain · Not yet recruiting

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.